Drug Sponsors

Report: 80% of pharma outsource some of their government reimbursement budgets

Monday, November 24, 2014 02:53 PM

Eighty percent of surveyed pharma companies outsource some portion of their government reimbursement budgets, including third-party audits that can help companies remain compliant to changing industry guidelines, according to Cutting Edge Information, a Research Triangle Park, N.C.-based pharmaceutical business intelligence provider.

More... »


SEC suspends trading in companies touting Ebola-related prevention/treatment operations

Monday, November 24, 2014 02:49 PM

The Securities and Exchange Commission has suspended trading in four companies that claim to be developing products or services in response to the Ebola outbreak, citing a lack of publicly available information about the companies' operations.

More... »

CenterWatch

AstraZeneca to expand its Maryland biologics manufacturing center, add 300 jobs

Monday, November 24, 2014 02:44 PM

AstraZeneca plans to expand its biologics manufacturing center in Frederick, Md. The more than $200 million project will increase production capacity at the facility to support AZ’s maturing pipeline, and will help the company keep pace with a growing demand for the development and use of biologics, which currently represent nearly 50% of AZ’s overall pipeline.

More... »

Apellis Pharmaceuticals to acquire Potentia Pharmaceuticals

Friday, November 21, 2014 11:18 AM

Apellis Pharmaceuticals, a Crestwood, Ky.-based, clinical stage immunotherapy company, will acquire Potentia Pharmaceuticals, an early stage biotechnology company also located in Crestwood. Apellis obtained the necessary intellectual property rights to develop its complement inhibitor drug compound (APL-2) in ophthalmology and plans its first clinical trial in dry age-related macular degeneration (dry AMD).

More... »

Shire to relocate 500 jobs, U.S. headquarters, to Massachusetts

Thursday, November 20, 2014 01:43 PM

Shire plans to relocate over 500 positions to Massachusetts from its Chesterbrook, Pa., site and establish Lexington, Mass., as the company’s U.S. operational headquarters. The transition is a continuation of the company’s “One Shire” efficiency program and will streamline business globally through two principal locations—Massachusetts and Switzerland—with support from a limited number of regional and country-based offices around the world.

More... »

Amgen, Novartis partner with Atlas Venture

Wednesday, November 19, 2014 02:37 PM

Atlas Venture, based in Cambridge, Mass., has entered into corporate strategic partnership (CSP) agreements with both Amgen, through its venture capital fund, Amgen Ventures, and Novartis. Atlas IX is expected to create and/or fund more than 15 new biotech companies and anticipates these new CSP relationships will be integral parts of facilitating their launch and progression.    

More... »

Ricerca Biosciences acquired by equity investment group Main Market Partners

Wednesday, November 19, 2014 02:14 PM

Ricerca Biosciences, based in Ohio, has been acquired by Main Market Partners, a middle-market growth investment fund in the same region. Terms of the sale have not been disclosed.

More... »

Report: Pharma is improving medicines access, but progress is uneven

Monday, November 17, 2014 02:30 PM

The world’s leading pharmaceutical companies are doing more to improve access to medicine in developing countries, with a raft of new initiatives, scale-ups and innovations over the last two years. However, the industry struggles to perform well in some practices that matter, according to the 2014 Access to Medicine Index, published by the Access to Medicine Foundation, a nonprofit organization based in the Netherlands that aims to advance access to medicine by encouraging the pharmaceutical industry to play a greater role in improving access to medicine in less developed countries.

More... »

Actavis to acquire Allergan for $66 billion

Monday, November 17, 2014 02:22 PM

Dublin-based Actavis, a global, integrated, specialty pharmaceutical company has announced it will acquire Allergan, a multi-specialty healthcare company based in Irvine, Calif., for approximately $66 billion, or $219 per share.

More... »

Precision Therapeutics changes name to Helomics, reorganizes management

Friday, November 14, 2014 10:51 AM

Precision Therapeutics has changed its name to Helomics, a Pittsburgh, Pa.-based, privately held comprehensive personalized healthcare company that develops next-generation diagnostics for the oncology field.

More... »

Link to survey
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs